Form 4: Pulmonx Officer Sells Shares for Tax, Receives New RSU Grant

Pulmonx's Chief Science & Technology Officer, Srikanth Radhakrishnan, sold 10,483 shares to cover tax obligations from RSU vesting and was granted 175,000 new Restricted Stock Units.

Summary

• Srikanth Radhakrishnan, Chief Science & Technology Officer of Pulmonx Corp (LUNG), engaged in multiple transactions on March 2, 2026.
• He sold a total of 10,483 shares of common stock at a price of $1.43 per share.
• These sales were specifically to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted on March 1, 2022, March 1, 2023, March 1, 2024, and March 3, 2025.
• Radhakrishnan was granted 175,000 new Restricted Stock Units (RSUs) at a price of $0.
• These newly granted RSUs will vest in equal quarterly installments over a four-year period, commencing from the grant date of March 2, 2026.
• Following these transactions, Radhakrishnan's direct beneficial ownership of common stock is 345,736 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The sales are routine for tax purposes, and the significant RSU grant demonstrates continued commitment and incentive alignment for a key officer.

Positives

• The grant of 175,000 new Restricted Stock Units (RSUs) to the Chief Science & Technology Officer indicates continued long-term incentive and alignment with shareholder interests.
• The RSUs vest over a four-year period, suggesting a sustained commitment from the officer to the company's future performance.

Negatives

• The sale of 10,483 shares, although for tax purposes, reduces the officer's direct ownership of common stock.

Future Outlook

The newly granted 175,000 Restricted Stock Units (RSUs) will vest in equal quarterly installments over a four-year period from March 2, 2026, indicating a future vesting schedule for a significant portion of the officer's compensation.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU grants and associated tax-related sales, are common occurrences in the biotechnology and medical device sectors. These transactions typically reflect standard executive compensation practices and do not inherently signal a change in company fundamentals or broader industry trends, unlike large, unprompted open-market sales.

Stakeholder Impact

• Shareholders: The grant of new RSUs aligns the Chief Science & Technology Officer's interests with long-term shareholder value creation, while the tax-related sales are a routine part of equity compensation and have minimal impact on overall share float.

Next Steps

• The 175,000 newly granted Restricted Stock Units (RSUs) will vest in equal quarterly installments over the four-year period from March 2, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions involving RSU grants and tax-related sales. Such transactions are standard for executive compensation and do not typically indicate a material change in the company's operational or financial outlook. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide sufficient new information to warrant a change in investment thesis.

Keywords

Pulmonx, LUNG, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Sale, Executive Compensation, Beneficial Ownership